The mass-metallicity relation at z~1-2 and its dependence on star formation rate

We present a new measurement of the gas-phase mass-metallicity relation (MZR), and its dependence on star formation rates (SFRs) at 1.3 < z < 2.3. Our sample comprises 1056 galaxies with a mean redshift of z = 1.9, identified from the Hubble Space Telescope Wide Field Camera 3 (WFC3) grism spectroscopy in the Cosmic Assembly Near-Infrared Deep Extragalactic Survey (CANDELS) and the WFC3 Infrared Spectroscopic Parallel Survey (WISP). This sample is four times larger than previous metallicity surveys at z ~ 2, and reaches an order of magnitude lower in stellar mass (10^8 M_sun). Using stacked spectra, we find that the MZR evolves by 0.3 dex relative to z ~ 0.1. Additionally, we identify a subset of 49 galaxies with high signal-to-noise (SNR) spectra and redshifts between 1.3 < z < 1.5, where H-alpha emission is observed along with [OIII] and [OII]. With accurate measurements of SFR in these objects, we confirm the existence of a mass-metallicity-SFR (M-Z-SFR) relation at high redshifts. These galaxies show systematic differences from the local M-Z-SFR relation, which vary depending on the adopted measurement of the local relation. However, it remains difficult to ascertain whether these differences could be due to redshift evolution, as the local M-Z-SFR relation is poorly constrained at the masses and SFRs of our sample. Lastly, we reproduced our sample selection in the IllustrisTNG hydrodynamical simulation, demonstrating that our line flux limit lowers the normalization of the simulated MZR by 0.2 dex. We show that the M-Z-SFR relation in IllustrisTNG has an SFR dependence that is too steep by a factor of around three.Comment: Accepted for publication in ApJ; 41 pages, 20 figure

Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences

The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

El tráfico de drogas y la política de los Estados Unidos en Colombia

La guerra en contra de las drogas en Colombia, respaldada por Washington y Bogotá durante esa década, no solamente fracasó en reducir el crecimiento del comercio y tráfico de drogas colombiano y la corrupción resultante, sino que probó en realidad ser contraproducent

Principales tendencias del siglo XXI en cuanto al crimen organizado, el narcotráfico y la democracia en la región

Discurso principal de la conferencia Tráfico de drogas en las américas: retos y desafíos celebrada en la Universidad Icesi el día 18 de septiembre de 2012

Narcotráfico, violencia política y políticas estadounidenses en Colombia durante los noventa

Este ensayo revisa el impacto de las políticas para el control de drogas de los gobiernos de Colombia y de Estados Unidos en lo referente al cultivo de drogas, el narcotráfico y la violencia política en Colombia durante los años noventa. La tesis central es que la guerra respaldada por Washington y Bogotá contra las drogas en Colombia a lo largo de la década no sólo fracasó en su propósito de reducir el creciente narcotráfico y la corrupción correspondiente, sino que de hecho demostró ser con..

El tráfico de drogas y la política de los Estados Unidos en Colombia

La guerra en contra de las drogas en Colombia, respaldada por Washington y Bogotá durante esa década, no solamente fracasó en reducir el crecimiento del comercio y tráfico de drogas colombiano y la corrupción resultante, sino que probó en realidad ser contraproducent